GlobeNewsWire
22 Sept 2026, 18:52 UTC · 3h ago
Verdict
Headline takes no side. We score NTHI +0.60 across three claims — strongly bullish.
+0.60strongly bullish
More positive than 72% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish · 1 new · 2 priced in
NeOnc reported a Phase 2a six-month progression-free survival of 48.9% for NEO100 versus a 20% benchmark (p=0.0047).
Priced inAugust 2026 Phase 2a readout
So whatWith 5 of 24 patients remaining on treatment, a larger trial will be needed to validate if this 28.9% delta persists.
More positive than 92% of claims this week
NeOnc plans to seek a Type B meeting with the FDA to discuss a potential registrational pathway for recurrent IDH1-mutant high-grade glioma.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Newpublished Sep 22, 2026
So whatThe outcome of this meeting will determine if the company can bypass larger Phase 2 trials for an accelerated approval path.
More positive than 76% of claims this week
NEO100 demonstrated a median overall survival of 26.09 months with no major toxicities reported across the cohort.
Priced inAugust 2026 Phase 2a readout
More positive than 62% of claims this week
Which stocks this story touches
More positive than 72% of ticker scores this week
The company reported positive Phase 2a readout results for NEO100 with progression-free survival exceeding benchmarks.
More negative than 79% of ticker scores this week
The company's Phase 3 TRIDENT study failed to meet its primary endpoint for overall survival.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
2h ago
+3.6%
Price agrees with the score
$3.45 vs $3.33 close before publication (Sep 21) · not market-adjusted
NTHI chart →